Evidence map›Paper›PMID 41351610›Full record

Trial reportJACC. Cardiovascular imaging2026

Stress Cardiac Magnetic Resonance Ischemia Burden and Cardiovascular Events: Post-Hoc Analysis From the ISCHEMIA Trial.

Raymond Y Kwong, Bobby Heydari, Siddique Abbasi, Francois-Pierre Mongeon, Francois Marcotte, Matthias Friedrich, Leslee J Shaw, Yifan Xu, Rebecca Anthopolos, Raffi Bekeredjian and 18 more

Registry-linked trialAbstract readRandomized Controlled TrialComparative StudyMulticenter Study
In one paragraph

Trial report in JACC. Cardiovascular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01471522 (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01471522 nacompletednot on this map

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

TypeinterventionalSponsorNYU Langone HealthRan2012 to 2023Enrolled5,179ConditionsCardiovascular Diseases, Coronary Disease, Coronary Artery Disease, Heart DiseasesArmscardiac catheterization, coronary artery bypass graft surgery, percutaneous coronary intervention, Lifestyle, Medication
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Highlights of the Society for Cardiovascular Magnetic Resonance 2025 conference: Leading the way to accessible, efficient, and sustainable cardiovascular magnetic resonance.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Raymond Y KwongDepartment of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: rykwong@bwh.harvard.edu.
Bobby HeydariDepartment of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Siddique AbbasiAmegen, Thousand Oaks, California, USA.
Francois-Pierre MongeonDepartment of Specialized Medicine, Division of Non-Invasive Cardiology, Montreal Heart Institute, Montreal, Quebec, Canada.
Francois MarcotteMayo Clinic, Phoenix, Arizona, USA.
Matthias FriedrichDepartment of Specialized Medicine, Division of Non-Invasive Cardiology, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.
Leslee J ShawIcahn School of Medicine at Mount Sinai, New York, New York, USA.
Yifan XuNYU Grossman School of Medicine, New York, New York, USA.
Rebecca AnthopolosNYU Grossman School of Medicine, New York, New York, USA.
Raffi BekeredjianRobert Bosch Medical Center, Stuttgart, Germany.
Lorenzo MontiIstituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.
Joseph SelvanayagamFlinders Medical Centre, Adelaide, South Australia, Australia.
Maciej LesiakUniversity Hospital of the Lords Transfiguration, Poznan, Poland.
Michael H PicardDepartment of Medicine, Cardiovascular Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Daniel S BermanCedars Sinai Medical Center, Los Angeles, California, USA.
Sripal BangaloreDuke Clinical Research Institute, Durham, North Carolina, USA.
John A SpertusSaint Luke's Mid America Heart Institute, Kansas City, Missouri, USA; University of Missouri-Kansas City's Healthcare Institute for Innovations in Quality, Kansas City, Missouri, USA.
Gregg W StoneThe Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
William E BodenVA New England Healthcare System, Bedford, Massachusetts, USA.
James MinCleerly Inc, New York, New York, USA.
G B John ManciniUniversity of British Columbia, Vancouver, British Columbia, Canada.
Jonathan LeipsicUniversity of British Columbia, Vancouver, British Columbia, Canada.
Matthew BudoffLundquist Institute, Harbor-UCLA Medical Center, Torrance, California, USA.
Cameron HagueCleerly Inc, New York, New York, USA.
Judith S HochmanCardiovascular Clinical Research Center, Leon H. Charney Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.
David J MaronDepartment of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Harmony R ReynoldsCardiovascular Clinical Research Center, Leon H. Charney Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.
ISCHEMIA Research Group

Funding

The Ischemia Trial - CCCU01HL105907 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HOCHMAN, JUDITH S · 2011 to 2019
$100.1M
The ISCHEMIA Trial - SDCCU01HL105462 · NHLBI · DUKE UNIVERSITY · PI ALEXANDER, KAREN P, O'BRIEN, SEAN M · 2011 to 2019
$17.8M
THE ISCHEMIA TRIAL - IICCU01HL105561 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SHAW, LESLEE J · 2011 to 2018
$6.5M
The ISCHEMIA Trial - EQOLU01HL105565 · NHLBI · DUKE UNIVERSITY · PI MARK, DANIEL B · 2011 to 2017
$2.4M
NHLBI NIH HHS U01 HL105462NHLBI NIH HHS U01 HL105561NHLBI NIH HHS U01 HL105565NHLBI NIH HHS U01 HL105907
6 · The paper itself

Abstract

backgroundResearch comparing the prognostic value of stress cardiac magnetic resonance (CMR) to other stress modalities in patients with coronary disease is limited.

objectivesThe authors compared the prognostic value of stress CMR vs alternative testing by either single-photon emission computed tomography or stress echocardiography (SPECT/echo) in the ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial.

methodsCMR vs SPECT/echo was compared in 3,909 patients randomized in ISCHEMIA after sites' interpretation of moderate to severe ischemia. Ischemia and infarct extent, measured by either CMR or SPECT/echo, were each associated with the trial's primary outcome of cardiovascular death, nonfatal myocardial infarction (MI), or hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest, at a median follow-up of 3.37 years (Q1-Q3: 2.20-4.56 years).

resultsCompared with SPECT/echo (n = 5,627), CMR participants (n = 313) were not different in key demographic factors but were more likely to have severe ischemia (57% vs 38%; P < 0.001) and to be randomized (n = 257, 82%, vs n = 3,652, 65%; P < 0.001). Ischemia severity (no/mild, moderate, severe) by CMR core laboratory was associated with cumulative 4-year event rates of all trial-specific endpoints, including the primary outcome (P = 0.042), cardiovascular death/MI (P = 0.041), and nonfatal MI (P = 0.03), but SPECT/echo ischemia severity was not. No/mild, moderate, and severe ischemia by CMR were associated with 0%, 14%, and 23% 4-year primary outcome rates, respectively, compared with 18%, 15%, and 16%, by SPECT/echo. After adjustment for age, estimated glomerular filtration rate, and diabetes, the association between ischemia extent and the primary endpoint differed by imaging modality, with each additional ischemic segment on CMR associated with a 13% increase in hazard (interaction P = 0.02). In participants assigned to initial conservative management who had no/mild ischemia on imaging, 4-year rates of invasive referral and coronary revascularization were lower in the CMR than SPECT/echo group (16.7% and 0%, respectively, for CMR; and 31% and 13.3%, respectively, for SPECT/echo).

conclusionsIschemia severity by CMR had a stronger association with all ISCHEMIA trial endpoints compared with SPECT/echo. (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches [ISCHEMIA]; NCT01471522).

Indexed as

Echocardiography, StressMagnetic Resonance ImagingMagnetic Resonance Imaging, CineMyocardial IschemiaTomography, Emission-Computed, Single-PhotonAgedAngina, UnstableFemaleHeart FailureHospitalizationHumansMaleMiddle AgedMyocardial InfarctionPredictive Value of TestsPrognosiscardiovascular eventsISCHEMIA trialstress cardiac magnetic resonance imaging

Identifiers

PMID41351610
PMCPMC13155462

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.